Here are the DEF 14A proxy statements from Utah Medical Products Inc (UTMD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow UTMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UTMD filings page.
Utah Medical Products, Inc. (UTMD) is asking stockholders to vote at the May 1, 2026 annual meeting on three items: electing two directors to terms expiring at the 2029 meeting, ratifying Haynie & Company as independent auditor for 2026, and an advisory vote approving the executive compensation program.
Only holders of 3,185,025 common shares outstanding as of March 2, 2026 may vote, with one vote per share. Directors and executive officers held 228,616 shares directly at the end of 2025, about 7% of the stock. In 2025 the CEO earned total pay of $341,709, while the median employee earned about $43,500, a pay ratio of roughly 1:8. The company highlights its profit-sharing bonus plan, nonqualified stock option plan, retirement contributions and group benefits as key elements of compensation, and discloses an executive clawback policy and a change-in-control agreement for the CEO.